ReviewFrontiers in pediatrics2021
Overview of Cardiomyopathies in Childhood.
Review in Frontiers in pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 41 citations in OpenAlex.
- Incidence, Genetic Characteristics, and Outcomes of Paediatric Cardiomyopathy in a National Cohort (2003-2025).Pediatric cardiology · 2026Article
- Assessment of miR-1-3p, miR-let-7b-5p, miR-21-5p, and miR-26b-5p in Children with Cardiovascular Diseases.Cells · 2026Article
- Review
- Pediatric cardiomyopathy in a resource-limited setting: clinical characteristics and determinants of medium-term outcomes.Frontiers in medicine · 2026Article
- The Influence of Arrhythmia on the Outcomes of Pediatric Patients with Idiopathic Dilated Cardiomyopathy.Pediatric cardiology · 2025Article
- Cardiomyopathy as the forgotten symptom of systemic lupus erythematosus in children: A case report.Narra J · 2025Article
- Prognosis of pediatric restrictive cardiomyopathy: more severe in sarcomeric variants.Frontiers in genetics · 2025Article
- Clinical characteristics and mortality risk factors in pediatric hypertrophic, restrictive, and rapidly progressive hypertrophic cardiomyopathy: a retrospective cohort study with follow-up.Frontiers in cardiovascular medicine · 2025Article
- Case Report: Multimodality imaging of a congenital ventricular septal aneurysm complicated by biventricular myocardial non-compaction in a child.Frontiers in pediatrics · 2025Article
- Metrnl and Cardiomyopathies: From Molecular Mechanisms to Therapeutic Insights.Journal of cellular and molecular medicine · 2025Review
- A Machine Learning Approach to Gene Expression in Hypertrophic Cardiomyopathy.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Cardiomyopathy in Children and Adolescents in the Era of Precision Medicine.Arquivos brasileiros de cardiologia · 2024Review
- Epidemiology of Pediatric Cardiomyopathy in a Mediterranean Population.Children (Basel, Switzerland) · 2024Article
- Cardiac MRI in diagnosis, prognosis, and follow-up of hypertrophic cardiomyopathy in children: current perspectives.The British journal of radiology · 2024Review
- RETRACTED: Left Ventricular Non-Compaction in Children: Aetiology and Diagnostic CriteriaDiagnostics (Basel, Switzerland) · 2024Review
- Pediatric dilated cardiomyopathy: a review of current clinical approaches and pathogenesis.Frontiers in pediatrics · 2024Review
- Focus on Paediatric Restrictive Cardiomyopathy: Frequently Asked Questions.Diagnostics (Basel, Switzerland) · 2023Review
- Administrative Databases: Friend or Foe in Paediatric Cardiomyopathy.CJC pediatric and congenital heart disease · 2023Article
- Biallelic variants in FLII cause pediatric cardiomyopathy by disrupting cardiomyocyte cell adhesion and myofibril organization.JCI insight · 2023Article
- Sarcomeric gene variants among Indians with hypertrophic cardiomyopathy: A scoping review.The Indian journal of medical research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paediatric cardiomyopathies are a heterogenous group of rare disorders, characterised by mechanical and electrical abnormalities of the heart muscle. The overall annual incidence of childhood cardiomyopathies is estimated at about 1 per 100,000 children and is significantly higher during the first 2 years of life. Dilated cardiomyopathies account for approximately half of the cases. Hypertrophic cardiomyopathies form the second largest group, followed by the less common left ventricular non-compaction and restrictive phenotypes. Infectious, metabolic, genetic, and syndromic conditions account for the majority of cases. Congestive heart failure is the typical manifestation in children with dilated cardiomyopathy, whereas presenting symptoms are more variable in other phenotypes. The natural history is largely influenced by the type of cardiomyopathy and its underlying aetiology. Results from a national population-based study revealed 10-year transplant-free survival rates of 80, 62, and 48% for hypertrophic, dilated and left ventricular non-compaction cardiomyopathies, respectively. Long-term survival rates of children with a restrictive phenotype have largely been obscured by early listing for heart transplantation. In general, the majority of adverse events, including death and heart transplantation, occur during the first 2 years after the initial presentation. This review provides an overview of childhood cardiomyopathies with a focus on epidemiology, natural history, and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.